On May 2, 2025, Transcode Therapeutics, Inc. announced that its stockholders approved a reverse stock split at a ratio of 1-for-28, which will be effective on a date to be determined later. The voting showed 6,431,663 in favor and 3,740,562 against the proposal, demonstrating significant support from shareholders.